Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

es that regulatory filings to support initiation of this clinical trial will be completed by mid-year 2007. Kosan plans to initiate a larger, international Phase 2/3 trial of alvespimycin in combination with trastuzumab in patients with HER2-positive metastatic breast cancer later in 2007.

Kosan also plans to pursue development of alvespimycin as a treatment for patients with acute myeloid leukemia (AML).

Kosan is also testing alvespimycin delivered orally in a Phase 1 dose escalation trial on both daily and every other day schedules. While dose escalation continues in this trial, early results have shown prolonged stable disease in patients with fibrosarcoma, hemangioendothelioma, melanoma and renal cell carcinoma with a favorable side effect profile.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global devel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:7/23/2014)... , July 23, 2014 On Tuesday, ... ("Plaintiff") filed suit in the 116 th ... , against RegenLab USA, LLC ... Prospective Business Relationships through false and misleading ... Business Disparagement through libel, disparagement, defamation, ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare ... Quality Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a ... Effective August 1, WVMI will launch Quality ... , Pennsylvania , ... and Louisiana.  The Network will engage providers and the ...
(Date:7/23/2014)... -- RT Oncology Services Corporation today announced that Craig ... directors. Mr. Mundie is currently senior advisor to the ... projects within the company and on technology strategy and ... officer. Mike Martin , president ... a visionary technology executive. His appointment is part of ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3
... , , WALTHAM, Mass., ... research and advisory firms for pharmaceutical and healthcare issues, finds ... cause the schizophrenia drug market to decrease from $6.3 billion ... States, France, Germany, Italy, Spain, the United Kingdom and Japan. ...
... , , BIRMINGHAM, Ala., Dec. 2 ... cancer. For adults 65 and over, the odds of losing vision are ... are one in six and odds of a woman developing breast cancer ... aging adults by increasing the risk of injuries, depression and inability to ...
Cached Medicine Technology:Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013 2Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2
(Date:7/23/2014)... 23, 2014 Recently, Agebc.com has launched ... the company is announcing a promotion of wedding dresses. ... will end at the end of this month. , ... popular styles, like A-line, mermaid, ball-gown, empire, and more. ... and other special-occasion dresses for women, and the company ...
(Date:7/23/2014)... July 23, 2014 Absolute PhysioCare and ... the launch of its custom orthotics and gait scan ... foot abnormalities in order to restore normal body balance. ... cause less fatigue and pain. In addition, Custom orthotics ... in the foot, resulting in relief and greater comfort ...
(Date:7/23/2014)... In his latest blog post at http://www.perwickstrom.com ... Per Wickstrom explains why entrepreneurs should plan for failure. ... he has never failed – and quite miserably at ... “Failure is not the opposite of success; it is ... reveals opportunities and shifts perspectives that, ultimately, are essential ...
(Date:7/23/2014)... 23, 2014 A Forever Recovery, an ... off to a great start and gives them a ... launched a new Internet Addiction section of its website ... to learn that Internet addiction is not just as ... but that it’s trapping more and more victims each ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 In its latest ... programs and believes that having family close by during a ... or not the process is successful, is focusing on a ... all drug and addiction-related dialogues: opiate abuse facts. , The ... , An overview of opiates, and why ...
Breaking Medicine News(10 mins):Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2Health News:Per Wickstrom’s Latest Blog Post Explains why Entrepreneurs Should Plan for Failure 2Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2
... expected to be launched in New Zealand soon, targeting ... Soon, men might also be given cervical cancer vaccines ... to protect themselves against several diseases. ... of cervical cancer prevention. Most cases of cervical cancer ...
... European Union has a huge health problem of having ... ailment in the Union, that costed the bloc’s members, a ... // ,Take a look at the annual ... disease ruled, making a dent of 230 euros on an ...
... that plays a crucial role in deciding if an embryo ... gene develops into a male), could explain the high incidence ... for formation of testes is also produced by Parkinson's affected ... and University of California. ,The SRY gene was ...
... A new research at the National Institutes of Health ... by modifying the lifestyle choices, such as exercise, learning ... published in the journal Alzheimer's & Dementia. ... Affairs for the Alzheimer's Association said that specific combinations ...
... said that the number of children born out of wedlock has ... The ONS Social// Trends survey also found that in 13 other ... ,The survey said that the size of the average UK household ... "Although most children are born to married couples, this substantial rise ...
... than famous, is now going to face some competition. Private ... Canada, having garnered enough support from the several provinces in ... the Quebec government, which intended to remove the ban on ... offered to chip in and pick up costs for such ...
Cached Medicine News:Health News:Men Might Get Their Share of Cervical Cancer Vaccine As Well 2Health News:Sex Determination Gene Blamed For High Incidence Of Parkinson’s In Me 2Health News:Cognitive deterioration in the older generation can be prevented by modifying the lifestyle 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: